Journal
HARVARD REVIEW OF PSYCHIATRY
Volume 18, Issue 5, Pages 293-303Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.3109/10673229.2010.511059
Keywords
-
Categories
Funding
- Intramural NIH HHS [Z99 MH999999] Funding Source: Medline
- NATIONAL INSTITUTE OF MENTAL HEALTH [ZIAMH002857, ZIAMH002828] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Mood disorders such as bipolar disorder and major depressive disorder are common, chronic, and recurrent conditions affecting millions of individuals worldwide. Existing antidepressants and mood stabilizers used to treat these disorders are insufficient for many. Patients continue to have low remission rates, delayed onset of action, residual subsyndromal symptoms, and relapses. New therapeutic agents able to exert faster and sustained antidepressant or mood-stabilizing effects are urgently needed to treat these disorders. In this context, the glutamatergic system has been implicated in the pathophysiology of mood disorders in unique clinical and neurobiological ways. In addition to evidence confirming the role of the glutamatergic modulators riluzole and ketamine as proof-of-concept agents in this system, trials with diverse glutamatergic modulators are under way. Overall, this system holds considerable promise for developing the next generation of novel therapeutics for the treatment of bipolar disorder and major depressive disorder.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
© Peeref 2019-2024. All rights reserved.